ritonavir (Norvir) Report issue

Small molecule Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Ritonavir binds to the protease active site and inhibits the activity of the enzyme. It is FDA approved for the treatment of HIV-1 infection. In patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving Ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. The most frequently reported adverse drug reactions among patients receiving Ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia.   NCATS

  • SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4
  • InChIKey: NCDNCNXCDXHOMX-XGKFQTDJSA-N
  • Mol. Mass: 720.944
  • ALogP: 5.91
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1.4258 - $8.3924
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( ritonavir (Norvir), lopinavir (Kaletra) - other names: lopinavir: ritonavir, lopinavir/ritonavir )
| |
( ritonavir (Norvir), ombitasvir (Viekira Pak), paritaprevir (viekira pak), dasabuvir (Exviera) - other name: dasabuvir, ombitasvir, paritaprevir, and ritonavir )
a 84538 | a-84538 | abbott-84538 | abt538 | abt-538 | lopinavir mixture with ritonavir | lopinavir / ritonavir | lopinavir/ritonavir | norvir | ombitasvir / paritaprevir / ritonavir | ritonavir | ritonavirum

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue